Enter to win every day in CTNOW's 21 Days of Summer Giveaways. Click here to see today's prize.
Topics

Ameet Sachdev

AbbVie beats expectations in 2Q, but shares drop over Humira overseas sales

AbbVie beats expectations in 2Q, but shares drop over Humira overseas sales

AbbVie reported better-than-expected second-quarter earnings, despite the impact of the strong U.S. dollar. But shares dropped in Friday morning trading on concerns of slower international sales of its blockbuster Humira drug. Here is a snapshot of the quarter: By the numbers: Net income was $1.36 billion, or 83 cents a share, in the period ended June 30, up from $1.09 billion, or 68 cents a share, a year ago. Excluding costs related to its Pharmacyclics acquisition, costs related to its separation from Abbott in 2013, restructuring charges and other special items, earnings were $1.08 a share, beating by 2 cents the average of 16 analysts' estimates compiled by Factset. Revenue...

Loading

82°